Drug Trial Radar · NCT07219420
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Nov 14, 2025
Primary completion
Dec 27, 2027
Study completion Nov 22, 2029
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Oct 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
Conditions
- Palmoplantar Pustulosis
Interventions
BimekizumabDrug
Study participants will receive bimekizumab at pre-specified time points.
PlaceboDrug
Study participants will receive matching placebo at pre-specified time points.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Palmoplantar pustulosis-Investigator Global Assessment 0/1 (PPP-IGA 0/1) response at Week 16Time frame: At Week 16
Locations
91 sites in 13 countries. Site status is shown where the registry gives one.
Ppp001 50754
Birmingham, Alabama · Recruiting
Ppp001 50176
Fremont, California · Recruiting
Ppp001 50746
Miami, Florida · Recruiting
Ppp001 50757
Auburn Hills, Michigan · Recruiting
Ppp001 50745
Columbus, Ohio · Recruiting
Ppp001 50202
Fairborn, Ohio · Recruiting
Ppp001 50733
Mayfield Heights, Ohio · Recruiting
Ppp001 50744
Oklahoma City, Oklahoma · Recruiting
Ppp001 50233
Barrie, Canada · Recruiting
Ppp001 50354
Calgary, Canada · Recruiting
Ppp001 50749
Fredericton, Canada · Recruiting
Ppp001 50765
London, Canada · Recruiting
Ppp001 50740
Québec, Canada · Recruiting
Ppp001 50752
Red Deer, Canada · Recruiting
Ppp001 50750
Surrey, Canada · Recruiting
Ppp001 20357
Beijing, China · Recruiting
Ppp001 20137
Chengdu, China · Recruiting
Ppp001 20352
Chengdu, China · Recruiting
Ppp001 20350
Chongqing, China · Recruiting
Ppp001 20311
Guangzhou, China · Recruiting
Ppp001 20313
Guangzhou, China · Recruiting
Ppp001 20022
Hangzhou, China · Recruiting
Ppp001 20193
Hangzhou, China · Recruiting
Ppp001 20344
Jinan, China · Recruiting
Ppp001 20355
Jinan, China · Recruiting
Ppp001 20345
Shanghai, China · Recruiting
Ppp001 20184
Shenzhen, China · Recruiting
Ppp001 20136
Tianjin, China · Recruiting
Ppp001 20356
Xi'an, China · Recruiting
Ppp001 20353
Yinchuan, China · Recruiting
Ppp001 40748
Plzen-bory, Czechia · Recruiting
Ppp001 40881
Ústí nad Labem, Czechia · Recruiting
Ppp001 40886
Hellerup, Denmark · Recruiting
Ppp001 40067
Lyon, France · Recruiting
Ppp001 40874
Nice, France · Recruiting
Ppp001 40887
Toulon, France · Recruiting
Ppp001 40875
Ahaus, Germany · Recruiting
Ppp001 40740
Bad Bentheim, Germany · Recruiting
Ppp001 40515
Berlin, Germany · Recruiting
Ppp001 40891
Bielefeld, Germany · Recruiting
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.